Janux Therapeutics Inc. Common Stock (JANX)

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical tri…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

113

Website

www.januxrx.com/

Fundamentals

1-day range

$16.96$17.72

Market cap

$981.85M

P/E (trailing)

—

P/E (forward)

-6.64

EPS (trailing)

$-1.64

Dividend yield

—

Beta

2.41

Avg. volume

984.3K

Forecasts

16 analyst ratings

Janux Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• JANX

  Janux Therapeutics Inc. Common Stock

  $18.01

  ▼ 4.10%
  Market cap $981.85MP/E —
  $12.12$35.34
• GERN

  Geron Corporation Common Stock

  $1.51

  ▼ 1.63%
  Market cap $1.01BP/E —
  $1.04$2.01
• OMER

  Omeros Corporation Common Stock

  $18.59

  ▼ 3.43%
  Market cap $951.74MP/E 14.37
  $3.94$19.65
• OLMA

  Olema Pharmaceuticals Inc. Common Stock

  $10.28

  ▼ 4.77%
  Market cap $1.03BP/E —
  $5.36$36.26
• ANNX

  Annexon Inc. Common Stock

  $4.97

  ▼ 5.33%
  Market cap $917.52MP/E —
  $2.03$7.18
• LXRX

  Lexicon Pharmaceuticals Inc. Common Stock

  $2.29

  ▼ 1.29%
  Market cap $1.05BP/E —
  $1.03$2.68
• AMPH

  Amphastar Pharmaceuticals Inc. Common Stock

  $22.01

  ▲ 0.59%
  Market cap $873.48MP/E 10.93
  $16.65$31.26

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
  benzinga · 8/24/2026
• This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
  Benzinga · 8/24/2026
• Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
  Benzinga · 8/24/2026
• Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
  Benzinga · 8/7/2026
• Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
  Yahoo · 8/6/2026
• Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
  Yahoo · 8/6/2026
• Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate
  Benzinga · 8/6/2026

• David Alan Campbell · July 31, 2026 · Gift

  123.8K
• David Alan Campbell · July 8, 2026 · Option Exercise

  7.0K @ $4.21
• Jake Simson · June 11, 2026 · Grant

  15.5K
• Jake Simson · June 11, 2026 · Grant

  5.5K
• Natasha Hernday · June 11, 2026 · Grant

  15.5K
• Natasha Hernday · June 11, 2026 · Grant

  5.5K
• Winston Kung · June 11, 2026 · Grant

  15.5K
• Winston Kung · June 11, 2026 · Grant

  5.5K
• Ronald W. Barrett · June 11, 2026 · Grant

  15.5K
• Ronald W. Barrett · June 11, 2026 · Grant

  5.5K
• RA Capital Healthcare Fund LP · June 11, 2026 · Grant

  15.5K
• RA Capital Healthcare Fund LP · June 11, 2026 · Grant

  5.5K
• Vickie L. Capps · June 11, 2026 · Grant

  15.5K
• Vickie L. Capps · June 11, 2026 · Grant

  5.5K
• Eric Dobmeier · June 11, 2026 · Grant

  15.5K

Institutional Ownership

March 31, 2026

Total shares held

58.45M

Total value held

$796.63M

Institutional holders

184